mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.056 |
0.1 |
mRNA |
Cytarabine |
CTRPv2 |
pan-cancer |
AAC |
-0.047 |
0.1 |
mRNA |
linifanib |
GDSC1000 |
pan-cancer |
AAC |
-0.058 |
0.1 |
mRNA |
vorinostat:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.058 |
0.1 |
mRNA |
BRD-K55116708 |
CTRPv2 |
pan-cancer |
AAC |
-0.061 |
0.1 |
mRNA |
STF-62247 |
GDSC1000 |
pan-cancer |
AAC |
0.054 |
0.1 |
mRNA |
PF-543 |
CTRPv2 |
pan-cancer |
AAC |
-0.062 |
0.1 |
mRNA |
EKB-569 |
GDSC1000 |
pan-cancer |
AAC |
0.054 |
0.1 |
mRNA |
PL-DI |
CTRPv2 |
pan-cancer |
AAC |
-0.051 |
0.1 |
mRNA |
CHIR-99021 |
GDSC1000 |
pan-cancer |
AAC |
0.051 |
0.1 |